

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

RIGEL PHARMACEUTICALS, INC.,

Petitioner,

v.

SERVIER PHARMACEUTICALS LLC

Patent Owner.

Case IPR2022-01423
U.S. Patent No. 10,610,125

PETITION FOR *INTER PARTES* REVIEW

TABLE OF CONTENTS

PETITIONER’S LIST OF EXHIBITS iii

I. INTRODUCTION.....1

II. MANDATORY NOTICES2

 A. Real Party-In-Interest (37 C.F.R. §42.8(b)(1)).....2

 B. Related Matters (37 C.F.R. §42.8(b)(2))2

 C. Counsel (37 C.F.R. §42.8(b)(3)) and Service Information (37 C.F.R. §42.8(b)(3)-(4)).....2

III. PAYMENT OF FEES3

IV. REQUIREMENTS FOR IPR.....3

 A. Grounds for Standing3

 B. Identification of Challenge4

V. BACKGROUND.....8

 A. Overview of Technology8

 B. The ’125 Patent.....9

 C. Prosecution History of the ’125 Patent.....15

 D. Asserted Prior Art.....18

VI. LEVEL OF ORDINARY SKILL IN THE ART23

VII. CLAIM CONSTRUCTION24

VIII. GROUNDS OF UNPATENTABILITY24

 A. The Challenged Claims are not entitled to any priority date24

 B. Ground 1: PM’678 anticipates the Challenged Claims57

 C. Ground 2: PM 2012 in view of PM’678 renders obvious the Challenged Claims63

 D. Ground 3: PM’678 (optionally together with PM 2012) in view of Dang’243 renders Challenged Claim 1269

 E. Ground 4: Dang’243 Anticipates Claims 1-5 and 9-1269

IX. NO SECONDARY CONSIDERATIONS.....75
XI. CONCLUSION.....75

PETITIONER’S LIST OF EXHIBITS

Exhibit	Description
1001	U.S. Patent No. 10,610,125 (“’125 Patent”)
1002	Excerpted Prosecution History of U.S. Patent No. 10,610,125
1003	Declaration of Professor David J. Sherman (“Sherman Dec.”)
1004	Curriculum Vitae of Professor David J. Sherman
1005	Declaration of Doctor Leslie Oleksowicz (“Oleksowicz Dec.”)
1006	Curriculum Vitae of Doctor Leslie Oleksowicz
1007	Mardis et al., <i>Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome</i> , 361 N. ENGL. J. MED. 1058 (2009). (“Mardis”)
1008	Vogelstein et al., U.S. Pat. App. Pub. No. 2011/0229479 (“Vogelstein”)
1009	Dang et al., Int’l Pat. App. Pub. No. 2010/105243 (“Dang ’243” or “2010 Application”)
1010	Popovici-Muller et al., Pat. App. Pub. No. 2012/009678 (“PM ’678”)
1011	Popovici-Muller et al., <i>Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo</i> , 3 ACS MED. CHEM. LETT. 850 (2012). (“PM 2012”)
1012	Zhao et al. <i>Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α</i> , 324 SCIENCE 261 (2009).
1013	Tostmann et al., <i>Protecting Chemistry Inventions: The Double-Edged Sword of Being an Unpredictable Art</i> , 6 ACS MED. CHEM. LETT. 364-6 (2015).
1014	Golub et al., <i>Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics</i> , 9 FRONT. ONCOL. 417 (2019). (“Golub”)
1015	Parsons et al., <i>An Integrated Genomic Analysis of Human Glioblastoma Multiform</i> , SCIENCEEXPRESS (2008). (“Parsons”)

Exhibit	Description
1016	Yan et al., <i>IDH1 and IDH2 Mutations in Gliomas</i> , 360 N. ENGL. J. MED. 765 (2009). (“Yan”)
1017	Bleeker et al., <i>IDH1 Mutations at Residue p.R132 (IDH1^{R132}) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors</i> , 30 HUMAN MUTATION 7 (2009). (“Bleeker”)
1018	Zernicka-Goetz et al., U.S. Pat. App. Pub. No. US 2003/0027783 (“Zernicka-Goetz”)
1019	Kang et al., <i>Mutational Analysis of IDH1 Codon 132 in Glioblastomas and Other Common Cancers</i> , 125 INT. J. CANCER 353 (2009). (“Kang”)
1020	U.S. Pat. App. No. 13/939,519, Excerpted Prosecution History (“ ’519 FH”)
1021	U.S. Pat. App. No. 13/256,396, Excerpted Prosecution History (“ ’396 FH”)
1022	Gross et al., <i>Cancer-associated Metabolite 2-hydroxyglutarate Accumulates in Acute Myelogenous Leukemia With Isocitrate Dehydrogenase 1 and 2 Mutations</i> , 207 J. EXP. MED. 339 (2010). (“Gross”)
1023	Salituro et al., Int’l Pat. App. Pub. No. 2011/072174
1024	Dang et al., <i>Cancer-associated IDH1 Mutations Produce 2-hydroxyglutarate</i> , 462 NATURE 739 (2009). (“Dang 2009”)
1025	U.S. Provisional Pat. App. No. 61/229,689, filed July 29, 2009 (“July 29, 2009 Provisional”)
1026	Gottlieb et al., Int’l Pat. App. Pub. no. 2006/016143 (“Gottlieb”)
1027	Shin et al., <i>Catechin Gallates are NADP⁺-competitive Inhibitors of Glucose-6-phosphate Dehydrogenase and Other Enzymes that Employ NADP⁺ as a Coenzyme</i> , 16 Bioorganic & Medicinal Chemistry (2008), 16, 3580-86

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.